Ariad Pharmaceuticals Inc fka ARIA

[DonShimoda]

With regard to Ariad, I don't think the "sell the news" strategy is the way to play ASCO this year. imo, very little of the recent gains are due to the anticipated positive Asco data but rather a reflection of 1) a reduction in the uncertainty associated with Merck filing the NDA and 2) increased recognition of the ponatinib opportunity, 3) validation of Ariads drug discovery capability and pipeline. How much of that is "baked" into todays price? At $9 or $10 bucks, my answer is "not enough".